Because of those demand increases, the medications were previously impacted by the nationwide drug shortage. But before ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

In order to enhance share liquidity and expand the number of investors trading in the companys shares, Sudarshan Pharma ...

Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based muscle disease biopharmaceutical company, increased its research ...

Analyst Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report) and keeping the price target ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it ...

Shanghai Henlius struck a deal in Saudi Arabia while XtalPi signed a partnership with Sinar Mas Multiartha in Indonesia.

With Trump back in office, India's pharma sector faces both opportunities and challenges. Increased tariffs may pose ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.